Zelda Therapeutics Ltd well-funded to advance cannabinoid …

Zelda Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) is well funded to make strong progress in 2018 with the development of cannabinoid-based formulations for the treatment of a variety of medical conditions.

The company’s cash at bank was $6.61 million at 31 December 2017 and it is fully funded for its near-term initiatives.

Zelda’s performance in the second half of 2017 has supported strengthening share prices with the company reaching a 5-year high of $0.16 in mid-February.

It is trading in the range of $0.14 and is up more than four times its 12-month low of a year ago.


...read more at http://www.proactiveinvestors.com.au/companies/news/192312/zelda-therapeutics-well-funded-to-advance-cannabinoid-treatments-for-medical-conditions-192312.html